Reviewer’s report

Title: Primary cardiac synovial sarcoma that was continuous with the mitral valve caused severe thrombocytopenia: a case report

Version: 0 Date: 22 Dec 2018

Reviewer: Hiroshi Kubota

Reviewer's report:

Zhang et al. described a case of primary cardiac synovial sarcoma with thrombocytopenia. It recovered early after tumor excision. They investigate bone marrow by aspiration and excluded thrombocytopenia caused by hematologic malignancies. The patient died of recurrence 6 months later. They conclude the thrombocytopenia might be one rare symptom of solid cardiac tumor.

The photos and pathological findings are impressive and valuable.

General remarks:
I read the MS with interest. It may include three major messages; 1: the rarity of the tumor and its pathological examination, 2: Secondary thrombocytopenia and its diagnosis and treatment, and 3: treatment of the cardiac malignant tumor.
About #1, it is well described. However, items #2, and #3 should be written more in detail.

Itemized remarks:
#2 Was there DVT?
Describe the pre- and postoperative data of D-dimer, FDP, Fibrinogen, PT, Protein-C, -S, APLA etc. concerning DIC or thrombotic microangiopathy.

"The tumor by its shape alters the atrial wall causing turbulence, which activates the platelets, thereby accelerating consumption." seems to be overstatement. Why do many other cardiac valvular diseases and aortic diseases which cause "turbulence" not always show thrombocytopenia?

#3.
The patient died 6 mo. After the operation. Was there local recurrence? Were there any metastatic (or primary) lesions at the end-stage? What is the cause of death?
Entire tumor resection could be done. Sudden death could be prevented but unfortunately the effect of the surgical resection is very limited, always. This is the major problem of the surgical resection of the cardiac malignant tumor lasting 3 or more decades. Why did the authors not recommend chemotherapy or radiotherapy to the Pt?
For the solitary cardiac malignancy, if fills the criterion, is heart Tx. permitted in China?

English revision by a native scientist is necessary.
Level of interest
Please indicate how interesting you found the manuscript:

An article of importance in its field

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no COI.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal